Joseph A. November is an Associate Professor in the Department of History at the University of South Carolina, affiliated with the McCausland College of Arts and Sciences. His research focuses on the history of biomedical computing, distributed computing, and the intersection of technology and medicine. He holds a Ph.D. from Princeton University (2006), an M.A. from the University of Chicago (2002), and a B.A. from Hamilton College (1997). His work includes the award-winning book Biomedical Computing: Digitizing Life in the United States (2012), which explores the co-development of biomedicine and computing technologies. Current projects include Revolutions@home , examining distributed computing in protein folding research, and a biography of computing pioneer Robert S. Ledley. He has received grants from the NSF, NIH, and the Charles Babbage Institute. Teaching interests span the history of science and technology, including courses on the history of medicine, digital humanities, and the role of games in historical education. He actively contributes to professional organizations like SHOT and the History of Science Society. Awards include the Computer History Museum Prize (2013) and the National Institutes of Health DeWitt Stetten Fellowship (2007-2008). His research bridges historical analysis with contemporary issues in technology and biomedical ethics.
Didier Trono is a Full Professor at École Polytechnique Fédérale de Lausanne (EPFL), where he leads the Laboratory of Virology and Genetics (LVG) within the School of Life Sciences. Formerly, from 2004 to 2012, he served as the founding dean of EPFL's Faculty of Life Sciences, orchestrating its development and growth during this formative period. Trono received his medical education at the University of Geneva, followed by clinical training in pathology, internal medicine, and infectious diseases in Geneva and at Massachusetts General Hospital in Boston. His scientific career began at the Whitehead Institute of MIT, and in 1990 he was recruited by the Salk Institute of San Diego to launch an AIDS research center. After seven years in the United States, he returned to Europe and eventually joined EPFL. Dr. Trono's research has evolved significantly over his career. Initially focusing on virus-host interactions, he studied pathogens like HIV and Hepatitis B virus, creating HIV-derived genetic transfer tools that are now successfully used in gene therapy. For approximately the last fifteen years, his research has centered on epigenetics, particularly exploring the impact of retroelements and their control mechanisms on development and physiology of higher organisms, including humans. His laboratory investigates how transposable elements and KRAB zinc finger proteins regulate gene expression, with important implications for understanding cancer biology and developing new diagnostic and therapeutic approaches. Analysis of his recent publications (2022-2024) reveals a strong focus on transposable elements, KRAB zinc finger proteins, and their roles in gene regulation and cancer. His work combines molecular biology, genomics, and bioinformatics approaches to understand how these ancient viral remnants have been co-opted by the host genome to regulate development and cellular functions. The research spans basic molecular mechanisms to potential clinical applications in cancer diagnosis and therapy, with some recent work also addressing SARS-CoV-2 and immune responses. Throughout his career, Professor Trono has mentored numerous PhD students, including Bojkowska Karolina, Brandão Sanches Vong Martins Filipe Amândio, Bulliard Yannick, Coluccio Andrea, Corsinotti Andrea, Coudray Alexandre, De Tribolet-Hardy Jonas Caspar, and Dorschel Iris Arianna. His laboratory has received significant funding to support research at the intersection of virology, genetics, and epigenetics, contributing to EPFL's reputation as a leading institution in life sciences research. The Trono Laboratory continues to be at the forefront of research on retroelements and their regulatory mechanisms, maintaining a vibrant research environment that bridges fundamental biological questions with potential medical applications, particularly in cancer research and precision medicine.
Ole Winther is Professor in High dimensional biological data analysis/Machine learning at the Department of Biology, University of Copenhagen and Professor in Data science and complexity at DTU Compute, Technical University of Denmark. He serves as CRO and co-founder of raffle.ai, CTO and co-founder of FindZebra, Head of ELLIS Unit Copenhagen, and co-PI of the Machine Learning for Life Science Center. His research spans Bioinformatics , Machine Learning , and AI for Science , focusing on applying deep learning to biological sequence analysis, latent variable models, and medical NLP. Winther's work develops predictive and generative models for bioinformatics, with significant contributions to protein localization tools (SignalP, DeepLoc, DeepTMHMM), single-cell genomics, and novel deep learning architectures like variational autoencoders and diffusion models. Analysis of Winther's recent publications (2023-2025) reveals a strong trend toward integrating protein language models with traditional bioinformatics approaches and applying diffusion models to scientific problems. His work bridges theoretical machine learning advancements with practical applications in biology and medicine, particularly in protein sequence analysis, medical search engines, and scientific simulation acceleration. Winther currently supervises a diverse research group including Panagiotis Antoniadis, Rachael M. DeVries, Jun Wang, Beatrix M. G. Nielsen, Felix G. Teufel, Irene R. Rodriguez, Anders Christensen, and Christopher Heje Grønbech. His former students have established successful careers at institutions including Google, Apple, and various startups, with notable alumni like Casper Sønderby (Google Brain) and Søren Sønderby (Apple). He leads significant research initiatives including the ELLIS Unit Copenhagen and the Machine Learning for Life Science Center, while maintaining active industry partnerships through his co-founded companies raffle.ai (enterprise search using NLP) and FindZebra (search engine for rare diseases). His teaching includes Deep Learning courses at both DTU (02456) and University of Copenhagen (NDAK24002U).
Yannis Paschalidis is a Distinguished Professor at Boston University with appointments in Electrical and Computer Engineering, Systems Engineering, Biomedical Engineering, and Computing & Data Sciences. He serves as Director of the Rafik B. Hariri Institute for Computing and Computational Science & Engineering. He holds a PhD (1996) and MS (1993) in Electrical Engineering and Computer Science from MIT, and a Diploma (1991) from the National Technical University of Athens. His interdisciplinary research spans optimization, control systems, machine learning, and data science with applications in healthcare, autonomous systems, and networks. Key focus areas include developing algorithms for autonomous navigation, healthcare analytics for clinical decision support, energy demand optimization, and computational biology for protein interaction modeling. Recent publications demonstrate strong focus on AI robustness (adversarial defenses, distributional robustness), healthcare applications (cognitive impairment detection, epidemic control), and sustainable systems (power networks, ecological forecasting). Methodological innovations center on reinforcement learning, distributionally robust optimization, and geometric analysis of classical algorithms. CAREER Award (NSF) IEEE Fellow (2014) IFAC Fellow (2022) IBM/IEEE Smarter Planet Award IEEE Computer Society Crowd Sourcing Prize IMIA Best Paper Award Charles DeLisi Award (2020) Distinguished Professor of Engineering As primary advisor to 35 PhD graduates, he leads the Network Optimization & Control (NOC) Lab. His research is funded by NSF, NIH, DoD, ARPA-E, and industry partners, including major grants on Neuro-Autonomy (ONR MURI), pandemic preparedness (ARPA-E NewRAMP), and healthcare AI (NIH QuBBD). He directs the Network Optimization & Control Lab focusing on optimization, learning, and control for autonomous systems, healthcare, and networks. The lab develops fundamental methodologies with applications in robotics, computational medicine, and infrastructure systems.
James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.
Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Michael Yeager, PhD, serves as an Associate Clinical Professor in the School of Medicine at the University of Colorado Denver, focusing on cardiopulmonary pathophysiology with emphasis on pulmonary hypertension and heart failure mechanisms. He completed his PhD at the University of Colorado Health Sciences Center in 2002, establishing foundational expertise in vascular biology. His research program investigates immunological and molecular drivers of pulmonary vascular disease, particularly the roles of autoantibodies, fibrocytes, and inflammatory cascades in disease progression. Analysis of his 14 publications (2012-2015) reveals consistent exploration of biomarker discovery, vascular remodeling, and immune dysregulation across pediatric and adult pulmonary hypertension. Key methodological approaches include proteomics, animal modeling, and molecular interrogation of cellular stress responses, with significant translational implications for personalized therapeutic strategies. Professional recognitions include: Outstanding Faculty award from Tau Beta Pi (2019) Chancellor's Teaching Recognition Award from the University of Colorado (2016) Dr. Yeager maintains active clinical research collaborations at Children's Hospital Colorado while mentoring within the medical school curriculum. His work bridges basic science discovery with clinical application through ongoing investigations into endothelial dysfunction and inflammatory mediators. Affiliated with the Department of Medicine, he contributes to pulmonary vascular research initiatives and participates in professional societies including the American Thoracic Society, American Heart Association, and T21 Research Society.
Laura Elo serves as Professor of Computational Medicine and Head of the Medical Bioinformatics Centre at the University of Turku, Finland. She concurrently holds the position of Research Director at Turku Bioscience Centre and acts as InFLAMES Flagship Contact, driving interdisciplinary biomedical research initiatives. Her academic foundation includes a PhD in Applied Mathematics (2007) and Adjunct Professorship in Biomathematics (2011), establishing her quantitative expertise before transitioning into biomedical applications. Her research program focuses on transforming molecular and clinical datasets through statistical modeling and advanced machine learning . Key thrusts include robust computational tools for proteome/epigenome analysis, AI-driven digital health diagnostics, and computational systems immunology for immune-mediated diseases. This work directly addresses challenges in reproducibility and scalability of high-throughput biotechnology data. Analysis of her recent publications reveals dominant themes in type 1 diabetes biomarker discovery , multi-omics integration , and immune system modeling , with strong emphasis on clinical translation through collaborations with experimental and medical teams. Her scientific recognition includes: JDRF Career Development Award Professor Elo actively trains MSc/PhD students and postdoctoral fellows while leading major research initiatives including ERC grants. Her teaching portfolio spans Bioinformatics Journal Club, AI in Diagnostics, and Systems Biology courses. The Elo Lab (https://elolab.utu.fi) operates as a hub for computational biomedicine, developing open-source tools like CellRomeR while maintaining close ties with Turku Bioscience Centre's experimental facilities for validating computational predictions in immunology and metabolic disease contexts.
David H. Sherman is the Hans W. Vahlteich Professor of Medicinal Chemistry at the University of Michigan, holding joint appointments in the College of Pharmacy (Department of Medicinal Chemistry), Medical School (Microbiology & Immunology), and College of Literature, Science, and the Arts (Chemistry). He leads the Sherman Lab at the Life Sciences Institute and co-founded the Natural Products Discovery Core. His research focuses on natural product discovery, biosynthetic pathways, and drug development for infectious diseases, cancer, and neurological disorders. Education: PhD in Synthetic Organic Chemistry from Columbia University (1981), BA in Chemistry from UC Santa Cruz (1978). Postdoctoral research at MIT (1984). Research interests include microbial secondary metabolites, enzymatic catalysis (e.g., C-H functionalization, polyketide assembly), and high-throughput drug screening. He pioneered a microbial natural product library with over 50,000 samples. Current projects emphasize developing macrolide antibiotics and advancing compounds toward clinical trials through the Natural Products Biosciences Initiative. Collaborations span global institutions, with a focus on biodiversity conservation and capacity-building in low-income nations. He has mentored 67 PhD students, 60 postdocs, and 85+ undergraduates, fostering interdisciplinary training in chemical biology and microbial biochemistry. Labs/Teams: Sherman Lab (Life Sciences Institute), Center Member at Samuel and Jean Frankel Cardiovascular Center, Center for Computational Medicine and Bioinformatics, Rogel Cancer Center.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Paul O'Toole is a Professor of Microbial Genomics and Principal Investigator at the APC Microbiome Ireland, University College Cork. His research focuses on the gut microbiome's role in health, aging, and disease, particularly in the context of diet and probiotics. He leads projects like the ELDERMET study on elderly nutrition and the NU-AGE project exploring Mediterranean diets' anti-aging effects. He holds a BA (Mod.) from Trinity College Dublin and a PhD from Lund University, with postdoctoral training in Canada and New Zealand. Key grants include studies on dairy-derived microbiota, probiotic strain improvement, and microbiome analysis in aging populations. He has published extensively on Lactobacillus genomics, gut-brain interactions, and microbiome-driven health outcomes. His work bridges fundamental microbiology with clinical applications, emphasizing translational research. Scientific highlights include discovering microbiome links to cognitive decline, demonstrating dietary modulation of gut microbes to combat obesity, and identifying keystone species in healthy aging. He advocates for sustainability in conservation and food systems, reflecting his interdisciplinary approach to global health challenges.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
